Invesco Ltd. Cuts Stake in Boston Scientific Corporation $BSX

Invesco Ltd. decreased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 21.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,318,177 shares of the medical equipment provider’s stock after selling 3,645,167 shares during the quarter. Invesco Ltd.’s holdings in Boston Scientific were worth $1,269,888,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of BSX. Norges Bank acquired a new stake in shares of Boston Scientific during the 4th quarter worth about $2,199,395,000. Egerton Capital UK LLP increased its stake in Boston Scientific by 223.7% in the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Maverick Capital Ltd. acquired a new stake in Boston Scientific during the fourth quarter worth approximately $280,735,000. Farallon Capital Management LLC raised its holdings in Boston Scientific by 56.7% during the fourth quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock worth $709,362,000 after purchasing an additional 2,693,007 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Boston Scientific by 31.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock worth $1,052,247,000 after buying an additional 2,668,230 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Up 0.8%

Shares of NYSE:BSX opened at $45.30 on Friday. Boston Scientific Corporation has a 1-year low of $44.44 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market cap of $67.33 billion, a P/E ratio of 18.95, a P/E/G ratio of 0.86 and a beta of 0.56. The firm has a fifty day moving average price of $55.05 and a 200 day moving average price of $73.22.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the business posted $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific declared that its board has authorized a share buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In related news, Director Edward J. Ludwig acquired 3,580 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 9,800 shares of company stock valued at $554,012 over the last quarter. 0.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on BSX shares. Mizuho cut their price target on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Citigroup decreased their price objective on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, May 28th. Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Needham & Company LLC reiterated a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a research report on Monday, May 18th. Finally, Jefferies Financial Group reduced their target price on Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $85.08.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.